Syndromic Multiplex Diagnostics Markets 2027–2031

Syndromic Multiplex Diagnostics Markets: Market Forecast, Competitive Landscape, Technology and Policy Outlook, 2027–2031 (8th Edition)

Global forecasts by syndrome, panel size, technology, setting and product, for 14 countries and regions, with 36 company profiles.

See the Table of Contents. GET the Free Sample of this Report.

Many organizations subscribe to all or some of our reports. You may already have free access to this report. FIND out Here.

Our Take

Syndromic testing, one sample tested for every likely cause of a syndrome, is entering its second phase. The post-pandemic respiratory reset hit the leaders, while new competitors, flexible pay-per-target panels and point-of-care systems widened the market. It grows from $3,520 million in 2026 to $5,100 million in 2031, at 7.7% a year, with point-of-care syndromic testing doubling and sequencing growing fastest of all.

Market Size 2026: USD $3.52B Market Size 2031: USD $5.1B CAGR: 7.7%

Situation Analysis: what is really happening

• The respiratory reset. bioMérieux's BIOFIRE respiratory panels fell 17% in the first half of 2026 while its non-respiratory panels grew 5.5%; respiratory panels are still the largest syndromes at $1,971.2 million.
• Competition arrives. The FDA cleared Cepheid's Xpert GI Panel in January 2026 and its Xpert Respiratory Panel in September, and QIAGEN completed its US blood culture identification panels in August and September.
• Labs pay for what they use. Selectable and pay-per-target panels grow 20.0% a year, from $123.2 million to $306.0 million, led by DiaSorin's LIAISON PLEX Flex panels and Quest Diagnostics' adoption of LIAISON PLEX.
• Testing moves to the bedside. Point-of-care syndromic testing doubles from $369.6 million to $739.5 million, and bioMérieux won a CLIA waiver for its SPOTFIRE Vaginitis Panel.
• Payers ease, slightly. Medicare's MolDX contractors eased the ordering-provider rule for syndromic panels in March 2026, while the 2027 fee schedule cuts loom.
• Owners change. QIAGEN agreed to be taken private by EQT, Waters now owns BD MAX, and Hologic is private.

Company Analysis: who is positioned, who is exposed

• bioMérieux, Qiagen, Roche and DiaSorin: Sample-to-answer syndromic leaders, facing the respiratory reset and a wave of new menus.
• Cepheid (Danaher), Waters, Abbott, Hologic and QuidelOrtho: Large molecular installed bases that are adding syndromic panels.
• Seegene, Applied BioCode, AusDiagnostics, altona, SpeeDx, Genetic Signatures and Credo: Batch laboratory and regional multiplex PCR specialists.
• Karius, Illumina, Oxford Nanopore, Delve Bio and BGI Genomics: Syndromic sequencing and metagenomics.
• Visby Medical, Bosch Vivalytic, Aptitude and Fluxergy: Point-of-care challengers.
• Sansure, Daan Gene, Bioperfectus and Molbio: Asian suppliers growing with China and India.

In all, 36 company profiles, each one to two pages with a fact box covering website, headquarters, ownership, revenue, employees and key products.

Questions this report answers

• How large is the syndromic testing market after the respiratory reset, and which syndromes grow fastest?
• Will pay-per-target and mid-size panels take share from comprehensive panels?
• How fast will point-of-care syndromic testing grow, and who will supply it?
• What do MolDX rules and the 2027 fee schedule mean for laboratory panel use?
• How will Cepheid, QIAGEN and DiaSorin's new menus change the competitive landscape?
• How large is each country market, and where is growth fastest?

What's inside

• 284 pages, 23 chapters, 67 tables and 50 figures
• Forecasts for 2027–2031 from a 2026 base year, by syndrome, panel size, technology, setting and product, for 14 countries and regions
• Respiratory and pneumonia panels, gastrointestinal and meningitis panels, and bloodstream, STI and other panels
• Panel size and reimbursement economics, technology, regulation and policy, and China, Asia-Pacific and emerging markets
• 10 market-moving developments from 2025 and 2026, SWOT, Porter's Five Forces and strategic recommendations
• 36 company profiles
• Download the Table of Contents (PDF)

Who buys this report

• Diagnostic companies and business development teams: plan syndromic menus, pricing models and point-of-care strategy.
• Laboratory and health-system leaders: choose platforms and panel sizes under tighter payer rules.
• Investors and analysts: model the post-pandemic syndromic market and its changing owners.
• Public health programmes: plan outbreak and surveillance testing.

Use independent research that makes you the expert. Your credit card order sends the report to your inbox instantly. Check all your licensing options, but don't worry: your order is available as a credit if you wish to upgrade.

See the Table of Contents. GET the Free Sample of this Report.

ABOUT THE LEAD AUTHOR

Mr. Greg Powell, B.Sc., M.B.A., is the President of Howe Sound Research. His education includes:

Finance for Senior Executives - Harvard Business School

Market Research - Burke Institute

M.B.A. (Finance and Policy) - University of British Columbia

B.Sc. (Chemistry) - University of British Columbia

He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years.